We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Thermo Fisher to Acquire Life Technologies for USD 13.6 Billion

By LabMedica International staff writers
Posted on 22 Apr 2013
Print article
Thermo Fisher Scientific (Waltham, MA, USA) and Life Technologies Corporation (Carlsbad, CA, USA) have signed a definitive agreement under which Thermo Fisher will acquire Life Technologies, creating enhanced capabilities for serving life science research, specialty diagnostics, and applied markets. The acquisition will take place for approximately USD 13.6 billion (plus the assumption of net debt at close—USD 2.2 billion as of yearend 2012).

The transaction will create a superior industry leader by building on both companies’ strengths for life sciences, such as proteomics, genomics, and cell biology. It will also strengthen technology and innovation leadership through complementary offerings that further broaden Thermo Fisher’s portfolio. Life Technologies provides innovative services and products (about 5,000 patents and licenses), offering a broad range of reagents, consumables, instruments, and systems. Life has an extensive offering of consumables for genomics, and molecular and cell biology and a range of technologies for bioproduction and forensics; it is also well known for its next-generation sequencing capability. These strengths, combined with Thermo Fisher’s leading offerings in analytical technologies and specialty diagnostics, create new convergence opportunities. The acquisition also enhances Thermo Fisher’s global reach. Life transacts more than half of its orders online through a highly regarded e-commerce platform. This leading capability, combined with Thermo Fisher’s extensive customer channels, creates a world-class infrastructure.


“This transaction enhances [...] our growth strategy: technological innovation, a unique customer value proposition, and expansion in emerging markets,” said Marc N. Casper, president and CEO of Thermo Fisher Scientific. Gregory T. Lucier, chairman and CEO of Life Technologies, said, “We look forward to joining forces with the outstanding team at Thermo Fisher, which shares our commitment to customers, employees, and the communities we serve.” Mr. Casper added, “Together we will be in an even stronger position to fulfill our company’s mission, which is to enable our customers to make the world healthier, cleaner, and safer.”

Related Links:

Thermo Fisher Scientific
Life Technologies


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Pathology

view channel
Image: Comparison of traditional histopathology imaging vs. PARS raw data (Photo courtesy of University of Waterloo)

AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis

The process of biopsy is important for confirming the presence of cancer. In the conventional histopathology technique, tissue is excised, sliced, stained, mounted on slides, and examined under a microscope... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.